Gefitinib or Erlotinib vs Chemotherapy for : Individual Patient Data Meta-Analysis of Overall SurvivalEGFR: Individual Patient Data Meta-Analysis of Overall Survival Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
Chee Khoon Lee; Lucy Davies; Yi-Long Wu; Tetsuya Mitsudomi; Akira Inoue; Rafael Rosell; Caicun Zhou; Kazuhiko Nakagawa; Sumitra Thongprasert; Masahiro Fukuoka; Sally Lord; Ian Marschner; Yu-Kang Tu; Richard J. Gralla; Val Gebski; Tony Mok; James Chih-Hsin Yang
Author Information: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia (CKL, LD, SL, IM, VG); Cancer Care Centre, St. George Hospital, Sydney, Australia (CKL); Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong, China (YLW); Division of Thoracic Surgery, Department of Surgery (TM), and Department of Medical Oncology (KM, MF), Kinki University Faculty of Medicine, Osaka-Sayama, Japan; Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan (AI); Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Barcelona, Spain (RR); Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China (CZ); Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand (ST); School of Medicine, The University of Norte Dame, Sydney, Australia (SL); Department of Statistics, Macquarie University, Sydney, Australia (IM); Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University (YKT, CHY); Albert Einstein College of Medicine, Jacobi Medical Center, NY (RJG); Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, China (TM).
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.